Women's Health
Mounjaro Benefits for Women Over 40: UK Guide
Quick Answer: The potential Mounjaro benefits for women include clinically meaningful weight loss and improvements in weight-related health risks when treatment is suitable. In SURMOUNT-1, participants had a mean age of 45 and 67.5% were women; however, the trial did not report a separate menopause-specific treatment effect. At 15 mg, average weight loss was 20.9% over 72 weeks across the overall trial population. Eligibility for the Mounjaro weight loss injection depends on BMI, medical history, current medicines and individual prescribing assessment.20.9%average weight loss at 15 mg over 72 weeks in SURMOUNT-1
45 yearsmean participant age in SURMOUNT-1
67.5%of SURMOUNT-1 participants were women
Content last updated: 8 October 2026
The Biology
Why Weight Management Can Change After 40
Women over 40 may experience changes in body composition, sleep, activity, appetite and fat distribution. The menopause transition is associated with a greater tendency to store fat around the abdomen, while ageing can reduce muscle mass and daily energy needs. These factors can make weight management feel different, although experiences vary widely.
Mounjaro does not replace menopause care and it is not licensed specifically for hormonal weight gain. It may be prescribed for weight management when the usual BMI and health criteria are met. A clinical assessment should also consider sleep, mental wellbeing, medicines, HRT, contraception, pregnancy plans and other possible causes of weight change. If you use an oral contraceptive, our guide to contraception while taking Mounjaro explains when additional protection is advised. Women managing polycystic ovary syndrome can read our Mounjaro and PCOS guide for the evidence, eligibility criteria and pregnancy considerations specific to PCOS. Some women also ask about herbal supplements in relation to insulin resistance or PCOS. Evidence on the benefits of berberine for women remains limited, and it should not replace assessment or prescribed treatment.
Menopause transition
Fat distribution may change
Falling oestrogen is associated with increased abdominal and visceral fat. This does not mean every woman gains weight or that menopause is the only cause.
Ageing
Muscle and energy needs can change
Gradual loss of lean mass can reduce energy needs. Resistance exercise and adequate protein are useful parts of a weight-management plan.
Sleep and symptoms
Indirect effects matter
Hot flushes, poor sleep, stress and low mood can affect eating and activity. These symptoms need appropriate menopause care rather than being treated as a direct indication for Mounjaro.
Metabolism
How Metabolism and Body Composition Change After 40
Ageing is commonly accompanied by a gradual loss of muscle mass, while the menopause transition can change where fat is stored. These changes may affect energy needs and increase abdominal fat, but they do not mean that weight loss is impossible or that every woman will respond in the same way.
Mounjaro supports weight management by reducing appetite and improving glucose-dependent insulin signalling. It should be used alongside a reduced-calorie diet and increased physical activity. Adequate protein, resistance exercise and a sustainable eating pattern can help protect lean mass during weight loss; see our guide to what to eat on Mounjaro for practical advice.
What the evidence shows: SURMOUNT-1 included adults across a broad age range and a majority of participants were women. Its results support tirzepatide for eligible adults, but they do not prove a unique or greater treatment effect specifically for women over 40 or for women going through menopause.
Mechanism
How Mounjaro Works for Women Over 40
Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. It reduces appetite, increases feelings of fullness and improves glucose-dependent insulin secretion. These actions are the same for eligible adults of different ages; treatment is not licensed specifically for menopause-related weight gain.
Weight and Waist-Circumference Changes
In SURMOUNT-1, tirzepatide produced clinically meaningful reductions in body weight and waist circumference across the overall study population. Because 67.5% of participants were women and the mean age was 45, the evidence is relevant to many women over 40, although personal results vary and cannot be predicted from the trial average.
Appetite and Eating Patterns
Reduced hunger may make a sustainable calorie deficit easier to maintain. Treatment still needs to be supported by adequate nutrition, physical activity and regular clinical review, particularly if appetite becomes so low that protein, fluids or micronutrient intake is difficult.
Mounjaro Compared With Wegovy
Tirzepatide and semaglutide work differently and average trial results differ, but neither medicine is automatically the best choice for every woman. Suitability, side effects, previous treatment response and personal preferences should guide the decision. Our Mounjaro vs Wegovy comparison explains the evidence and practical differences.
Expected Results
Expected Mounjaro Results for Women Over 40
There is no single expected result for women over 40. In SURMOUNT-1, average weight change at 72 weeks was 15.0% with 5 mg, 19.5% with 10 mg and 20.9% with 15 mg, compared with 3.1% with placebo. These figures describe the overall trial groups and should not be read as a promise of individual results.
Dose increases are gradual and based on tolerability; the highest dose is not necessary or suitable for everyone. See the Mounjaro dose schedule for the usual UK titration steps.
| SURMOUNT-1 group | Average weight change at 72 weeks | Context |
|---|---|---|
| Tirzepatide 5 mg | 15.0% reduction | Overall trial average, not women-only data |
| Tirzepatide 10 mg | 19.5% reduction | Overall trial average, not women-only data |
| Tirzepatide 15 mg | 20.9% reduction | Overall trial average, not women-only data |
| Placebo | 3.1% reduction | All groups also received lifestyle support |
Track more than scale weight: Your prescriber may also review waist circumference, blood pressure, blood glucose, side effects, nutrition, strength and how treatment affects everyday life. A slower or less linear response can still be clinically meaningful.
Safety
Safety Considerations for Women Over 40 on Mounjaro
Mounjaro is a prescription-only medicine and requires an individual clinical assessment. Before you buy Mounjaro online, the prescribing team should review your BMI, medical history, current medicines, contraception, pregnancy plans and any HRT.
Common reactions include nausea, diarrhoea, vomiting, abdominal pain and constipation. Read our Mounjaro side effects guide for practical advice and warning signs.
| Consideration | What to know | What to discuss |
|---|---|---|
| Pregnancy | Tirzepatide should not be used during pregnancy | Stop at least one month before a planned pregnancy and speak to your prescriber |
| Oral contraception | Effectiveness may be reduced after starting treatment and after dose increases | Use a barrier method or switch to non-oral contraception for four weeks after starting and for four weeks after each dose increase |
| HRT | Delayed gastric emptying may affect absorption of oral HRT, particularly oral progestogens | Ask the clinician managing your HRT to review the formulation and dose |
| Gallbladder and pancreas | Gallbladder problems and acute pancreatitis are recognised safety concerns | Seek urgent advice for severe, persistent abdominal pain |
| Other medicines | Delayed gastric emptying may affect the absorption timing of some oral medicines | Provide a complete medication and supplement list |
| Nutrition and muscle | Rapid weight loss and very low intake can make it harder to meet nutritional needs | Discuss protein intake, resistance exercise and any persistent vomiting or poor intake |
Mounjaro & Menopause
Mounjaro, Perimenopause and HRT
Mounjaro does not treat menopause symptoms such as hot flushes or night sweats. It may be considered for weight management when a woman meets the licensed eligibility criteria, whether or not she is in perimenopause or menopause. Our dedicated guide to Mounjaro and menopause covers this topic in more depth.
Can Mounjaro and HRT Be Used Together?
They may be used together following clinical review, but the HRT formulation matters. British Menopause Society guidance highlights concern that delayed gastric emptying from incretin-based medicines could reduce absorption of oral HRT, particularly oral progestogens used to protect the womb lining. Evidence is limited, so treatment should be reviewed by the clinician managing your HRT rather than adjusted without advice.
Women using oral oestrogen may be advised to consider transdermal oestrogen, while women using oral progesterone may need a different route or a clinician-led dose review. Report unscheduled bleeding and make sure both prescribers know about all treatments you use.
Choosing Between Mounjaro and Wegovy
Head-to-head evidence shows greater average weight loss with tirzepatide than semaglutide in the overall study population, but the study did not establish a special advantage for menopausal women. A prescriber should consider eligibility, side effects, previous response and personal circumstances before recommending either treatment.
Key Questions
Mounjaro Benefits for Women: What the Evidence Can Tell Us
Does Mounjaro work for women over 40?
Women made up 67.5% of SURMOUNT-1 participants and the mean age was 45, so many women over 40 were represented. The trial supports substantial average weight loss in eligible adults, but it did not publish a separate estimate for women over 40 or prove that menopause changes the medicine's effect.
Why can weight management change after 40?
Ageing, menopause-related changes in fat distribution, loss of muscle mass, sleep disruption, medicines and lifestyle can all contribute. The balance differs between individuals, so assessment should consider the whole health picture rather than assume hormones are the only cause.
FAQs
Frequently Asked Questions: Mounjaro for Women Over 40
For eligible women, benefits may include clinically meaningful weight loss and improvements in weight-related risk factors. SURMOUNT-1 included 67.5% women, but results were reported for the overall study population rather than specifically for women over 40 or women in menopause.
Perimenopause itself does not prevent prescribing. You must still meet the licensed weight-management criteria and complete a clinical assessment. Mounjaro treats weight management; it does not treat menopause symptoms.
They may be used together, but British Menopause Society guidance recommends reviewing oral HRT because delayed gastric emptying may affect absorption, particularly of oral progestogens. Do not change HRT yourself; ask the clinician managing it to review the formulation and dose.
In women with overweight or obesity, reduced effectiveness of oral contraceptives cannot be excluded. UK prescribing information advises using a barrier method or switching to non-oral contraception for four weeks after starting Mounjaro and for four weeks after each dose increase.
Head-to-head evidence found greater average weight loss with tirzepatide than semaglutide in the overall trial population. It did not prove a unique advantage specifically for women over 40, so the most suitable treatment depends on medical history, side effects, previous response and prescribing assessment.
Mounjaro should not be used during pregnancy. UK prescribing information says tirzepatide should be stopped at least one month before a planned pregnancy. Speak to your prescriber before stopping or changing treatment.
Ready to Start Mounjaro Treatment?
GPhC-registered pharmacy (No. 9013192) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Check Eligibility Today →
Sources: UK Mounjaro Summary of Product Characteristics and Patient Information Leaflet (electronic Medicines Compendium, updated 2026) | Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216 | British Menopause Society. Use of incretin-based therapies in women using HRT. 2025 | NICE TA1026. Tirzepatide for managing overweight and obesity. Educational information only; individual assessment is required.